A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

(2011) R. L. Piekarz et al.   BLOOD

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

(2011) M. J. Bishton et al.   BLOOD

Multiple Myeloma

(2010) Jacob Laubach et al.   Annual Review of Medicine

NF- B-induced chromatin remodeling regulates angiogenesis

(2010) D. Keskin et al.   BLOOD

Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

(2010) J. Kikuchi et al.   BLOOD

Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma

(2010) P A Thompson et al.   BONE MARROW TRANSPLANTATION

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

(2010) Ruben Niesvizky et al.   CANCER

The DAC system and associations with multiple myeloma

(2010) Enrique M. Ocio et al.   INVESTIGATIONAL NEW DRUGS

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

(2010) Michael Dickinson et al.   INVESTIGATIONAL NEW DRUGS

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

(2010) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)

(2009) M. Roussel et al.   BLOOD

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

(2009) A. Badros et al.   CLINICAL CANCER RESEARCH

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

(2009) H Quach et al.   LEUKEMIA

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

(2008) Paul Richardson et al.   LEUKEMIA & LYMPHOMA